Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Developing aptamers into therapeutics
Rebekah R. White, … , Bruce A. Sullenger, Christopher P. Rusconi
Rebekah R. White, … , Bruce A. Sullenger, Christopher P. Rusconi
Published October 15, 2000
Citation Information: J Clin Invest. 2000;106(8):929-934. https://doi.org/10.1172/JCI11325.
View: Text | PDF
Perspective

Developing aptamers into therapeutics

  • Text
  • PDF
Abstract

Authors

Rebekah R. White, Bruce A. Sullenger, Christopher P. Rusconi

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Decoy RNA corresponding to the TAR RNA sequence competes with the viral ...
Decoy RNA corresponding to the TAR RNA sequence competes with the viral encoded sequence for binding of tat protein. By sequestering the tat protein from the real TAR RNA sequence present in the HIV viral RNA, the decoy RNA can inhibit HIV RNA transcription and thus reduce viral replication.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts